

Pharmacy Formulary Updates Effective 1/1/2020

The MVP Health Care® (MVP) Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require **prior authorization** for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at mvphhealthcare.com.

New Drugs (prior authorization required)

Drug Name	Indication	Commercial & Marketplace Tier	Medicare Part D Tier	MVP Medicaid
Rinvoq	Rheumatoid Arthritis	Tier 2	Non-formulary	Tier 2
Xenleta	Community-Acquired Bacterial Pneumonia	Tier 3	Non-formulary	Non-formulary
Nourianz	Parkinson's Disease	Tier 3	Non-formulary	Non-formulary
Wakix	Narcolepsy	Tier 3	Non-formulary	Non-formulary
Inrebic	Myelofibrosis	Tier 3	Tier 5	Non-formulary
Nayzilam	Epilepsy	Tier 3	Non-formulary	Non-formulary
Tosymra	Migraines	Tier 3	Non-formulary	Non-formulary
Rybelsus	Diabetes	Tier 3	Non-formulary	Non-formulary
Gvoke	Diabetes	Tier 3	Non-formulary	Non-formulary
Proair Digihaler	Asthma	Tier 3	Non-formulary	Non-formulary
Duaklir Pressair	Chronic Obstructive Pulmonary Disease (COPD)	Tier 3	Non-formulary	Non-formulary
Myxredlin	Diabetes	Medical	Non-formulary	Medical

For Commercial & Exchange (non-Medicare) business:

New generic formulary additions	
Drug Name	Tier
posaconazole (Noxafil)	1 (Tier 2 Exchange)
aminocaproic oral solution (Amicar)	1 (Tier 2 Exchange)
nitisinone (Orfadin)	1 with PA (Tier 2 with PA Exchange)